Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.Market Watch • 10/16/25
The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 200%Investors Business Daily • 10/16/25
ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate UpdateBusiness Wire • 09/29/25
PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 09/15/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAXPRNewsWire • 09/13/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAXGlobeNewsWire • 09/02/25
Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy PipelineGlobeNewsWire • 08/25/25
PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law FirmPRNewsWire • 08/14/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Praxis Precision Medicines, Inc. - PRAXGlobeNewsWire • 08/09/25
Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law FirmGlobeNewsWire • 08/05/25
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsGlobeNewsWire • 08/04/25
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic EncephalopathiesGlobeNewsWire • 07/17/25
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock UpsideBenzinga • 05/07/25
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial ResultsGlobeNewsWire • 05/02/25
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic EncephalopathiesGlobeNewsWire • 04/08/25
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)Seeking Alpha • 03/04/25
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/28/25
Praxis Precision Medicines Provides Update on Essential3 and Corporate UpdateGlobeNewsWire • 02/28/25
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/25/25